Okamoto K - Search Results

1

Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.

Okamoto K, Ikemori-Kawada M, Jestel A, von König K, Funahashi Y, Matsushima T, Tsuruoka A, Inoue A, Matsui J. Okamoto K, et al. ACS Med Chem Lett. 2014 Nov 17;6(1):89-94. doi: 10.1021/ml500394m. eCollection 2015 Jan 8. ACS Med Chem Lett. 2014. PMID: 25589937 Free PMC article.

2

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.

Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, Tsuruoka A. Okamoto K, et al. Cancer Lett. 2013 Oct 28;340(1):97-103. doi: 10.1016/j.canlet.2013.07.007. Epub 2013 Jul 12. Cancer Lett. 2013. PMID: 23856031 Free article.

3

Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.

Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y. Tohyama O, et al. Among authors: okamoto k. J Thyroid Res. 2014;2014:638747. doi: 10.1155/2014/638747. Epub 2014 Sep 10. J Thyroid Res. 2014. PMID: 25295214 Free PMC article.

4

E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.

Watanabe Miyano S, Yamamoto Y, Kodama K, Miyajima Y, Mikamoto M, Nakagawa T, Kuramochi H, Funasaka S, Nagao S, Sugi NH, Okamoto K, Minoshima Y, Nakatani Y, Karoji Y, Ohashi I, Yamane Y, Okada T, Matsushima T, Matsui J, Iwata M, Uenaka T, Tsuruoka A. Watanabe Miyano S, et al. Among authors: okamoto k. Mol Cancer Ther. 2016 Nov;15(11):2630-2639. doi: 10.1158/1535-7163.MCT-16-0261. Epub 2016 Aug 17. Mol Cancer Ther. 2016. PMID: 27535969

5

Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.

Matsuki M, Adachi Y, Ozawa Y, Kimura T, Hoshi T, Okamoto K, Tohyama O, Mitsuhashi K, Yamaguchi A, Matsui J, Funahashi Y. Matsuki M, et al. Among authors: okamoto k. Cancer Sci. 2017 Apr;108(4):763-771. doi: 10.1111/cas.13169. Epub 2017 Apr 20. Cancer Sci. 2017. PMID: 28107584 Free PMC article.

6

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.

Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, Tohyama O, Uehara T, Kimura T, Watanabe H, Asano M, Kawano S, Tizon X, McCracken PJ, Matsui J, Aoshima K, Nomoto K, Oda Y. Funahashi Y, et al. Among authors: okamoto k. Cancer Sci. 2014 Oct;105(10):1334-42. doi: 10.1111/cas.12488. Epub 2014 Sep 16. Cancer Sci. 2014. PMID: 25060424 Free PMC article.

7

Synthesis and structure-activity relationships of novel, potent, orally active hypoxia-inducible factor-1 inhibitors.

Nagao S, Yamane Y, Funasaka S, Tanaka K, Miyazaki K, Kotake Y, Kamata J, Watanabe-Miyano S, Toyama O, Ozawa Y, Mizui Y, Okamoto K, Ito D. Nagao S, et al. Among authors: okamoto k. Bioorg Med Chem. 2014 Oct 1;22(19):5513-29. doi: 10.1016/j.bmc.2014.07.020. Epub 2014 Jul 30. Bioorg Med Chem. 2014. PMID: 25139751

8

Microregional antitumor activity of a small-molecule hypoxia-inducible factor 1 inhibitor.

Okamoto K, Ito D, Miyazaki K, Watanabe S, Tohyama O, Yokoi A, Ozawa Y, Asano M, Kawamura T, Yamane Y, Nagao S, Funasaka S, Kamata J, Kotake Y, Aoki M, Tsukahara N, Mizui Y, Tanaka I, Sawada K. Okamoto K, et al. Int J Mol Med. 2012 Apr;29(4):541-9. doi: 10.3892/ijmm.2011.875. Epub 2011 Dec 29. Int J Mol Med. 2012. PMID: 22211243 Free PMC article.

9

Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.

Narita Y, Okamoto K, Kawada MI, Takase K, Minoshima Y, Kodama K, Iwata M, Miyamoto N, Sawada K. Narita Y, et al. Among authors: okamoto k. Mol Cancer Ther. 2014 Apr;13(4):823-32. doi: 10.1158/1535-7163.MCT-13-0667. Epub 2014 Jan 21. Mol Cancer Ther. 2014. PMID: 24448821

10

Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities.

Mizui Y, Sakai T, Iwata M, Uenaka T, Okamoto K, Shimizu H, Yamori T, Yoshimatsu K, Asada M. Mizui Y, et al. Among authors: okamoto k. J Antibiot (Tokyo). 2004 Mar;57(3):188-96. doi: 10.7164/antibiotics.57.188. J Antibiot (Tokyo). 2004. PMID: 15152804 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,320 results

Search Page